105 related articles for article (PubMed ID: 6660046)
1. Increased plasma free dopamine after treatment with atenolol and oxprenolol in essential hypertension.
Kjeldsen SE; Eide I; Aakesson I; Amundsen R; Eriksen IL; Leren P
Acta Med Scand; 1983; 214(5):367-71. PubMed ID: 6660046
[TBL] [Abstract][Full Text] [Related]
2. Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade.
Leenen FH; Davies RA; Fourney A
Clin Pharmacol Ther; 1998 Nov; 64(5):522-35. PubMed ID: 9834044
[TBL] [Abstract][Full Text] [Related]
3. Long-term beta 1-adrenergic blockade restores adrenomedullary activity in primary hypertension.
Jacobs MC; Lenders JW; Smits P; Willemsen JJ; Tack C; Thien T
J Cardiovasc Pharmacol; 1997 Sep; 30(3):338-42. PubMed ID: 9300318
[TBL] [Abstract][Full Text] [Related]
4. Plasma noradrenaline concentration in essential hypertension during long-term beta-adrenoceptor blockade with oxprenolol.
Jones DH; Daniel J; Hamilton CA; Reid JL
Br J Clin Pharmacol; 1980 Jan; 9(1):27-31. PubMed ID: 7356889
[TBL] [Abstract][Full Text] [Related]
5. Increased plasma vasopressin and serum uric acid in the low renin type of essential hypertension.
Skjøtø J; Aakesson I; Os I; Kjeldsen SE; Eide I; Leren P
Acta Med Scand; 1984; 215(2):165-72. PubMed ID: 6367368
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of atenolol and oxprenolol in the treatment of arterial hypertension. A comparison.
Turner AS; Watson OF; Brocklehurst JE
Med J Aust; 1979 Jun; 1(13):625-6. PubMed ID: 386061
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma adrenaline concentrations in benign essential hypertension.
Franco-Morselli R; Elghozi JL; Joly E; Di Giuilio S; Meyer P
Br Med J; 1977 Nov; 2(6097):1251-4. PubMed ID: 589124
[TBL] [Abstract][Full Text] [Related]
8. Effects of atenolol and hydrochlorothiazide on blood pressure and plasma catecholamines in essential hypertension.
Myers MG; de Champlain J
Hypertension; 1983; 5(4):591-6. PubMed ID: 6862582
[TBL] [Abstract][Full Text] [Related]
9. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension.
Petrie JC; Jeffers TA; Robb OJ; Scott AK; Webster J
Br Med J; 1980 Jun; 280(6231):1573-4. PubMed ID: 7000243
[TBL] [Abstract][Full Text] [Related]
10. Decreased platelet-free dopamine and unchanged noradrenaline and adrenaline in essential hypertension.
Kjeldsen SE; Gjesdal K; Leren P; Eide IK
Thromb Haemost; 1988 Oct; 60(2):251-4. PubMed ID: 3217920
[TBL] [Abstract][Full Text] [Related]
11. Sympathetic reflex responses during treatment of essential hypertension with hydrallazine and oxprenolol.
Davies IB; Sever PS; Rosenthal T
Br J Clin Pharmacol; 1979 Jul; 8(1):49-51. PubMed ID: 399592
[TBL] [Abstract][Full Text] [Related]
12. Dopamine-beta-hydroxylase activity and catecholamine concentrations in plasma: experimental and essential hypertension.
Grobecker H; Saavedra JM; McCarty R; Chiueh CC; Kopin IJ
Postgrad Med J; 1977; 53 Suppl 3():43-8. PubMed ID: 928266
[No Abstract] [Full Text] [Related]
13. Comparative study of oxprenolol and atenolol in the treatment of hypertension.
Kamili MA; Allaqaband GQ; Ali G; Shah MY; Sheikh AS
Indian Heart J; 1988; 40(6):471-4. PubMed ID: 3248806
[No Abstract] [Full Text] [Related]
14. Plasma adrenaline and noradrenaline in essential hypertension and after long-term treatment with beta-adrenoreceptor-blocking agents.
Franco-Morselli R; Baudouin-Legros M; Meyer P
Clin Sci Mol Med Suppl; 1978 Dec; 4():97s-100s. PubMed ID: 32010
[TBL] [Abstract][Full Text] [Related]
15. Decreased peripheral dopaminergic activity in essential hypertension?
Kjeldsen SE; Flaaten B; Eide I; Helgeland A; Leren P; Fønstelien E
Scand J Clin Lab Invest; 1983 Feb; 43(1):15-20. PubMed ID: 6622964
[TBL] [Abstract][Full Text] [Related]
16. Effect of sampling site and conditions on plasma levels of noradrenaline, adrenaline and dopamine.
Saar N; Jackson R; Bachmann A; Gordon R
Prog Biochem Pharmacol; 1980; 17():90-7. PubMed ID: 7208507
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytoma associated ventricular tachycardia blocked with atenolol.
Michaels RD; Hays JH; O'Brian JT; Shakir KM
J Endocrinol Invest; 1990 Dec; 13(11):943-7. PubMed ID: 2090675
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension.
Wilcox RG; Hampton JR
Br Heart J; 1981 Nov; 46(5):498-502. PubMed ID: 6119103
[TBL] [Abstract][Full Text] [Related]
19. The effect on HDL cholesterol of oxprenolol and atenolol.
Kjeldsen SE; Eide I; Leren P; Foss OP; Holme I; Eriksen IL
Scand J Clin Lab Invest; 1982 Sep; 42(5):449-53. PubMed ID: 6130595
[TBL] [Abstract][Full Text] [Related]
20. The relative antihypertensive potency of propranolol, oxprenolol, atenolol, and metoprolol given once daily. A double-blind, crossover, placebo-controlled study in ambulatory patients.
Ravid M; Lang R; Jutrin I
Arch Intern Med; 1985 Jul; 145(7):1321-3. PubMed ID: 4015285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
